Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: Directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

Annals of Oncology

Volumn 29, Issue 5, 2018, Pages 1235-1248

  Sydes, M R ^a   Spears, M R ^a   Mason, M D ^b   Clarke, N W ^c   Dearnaley, D P ^d   de Bono, J S ^d   Attard, G ^e   Chowdhury, S ^f   Cross, W ^g   Gillessen, S ^h,i,j   Malik, Z I ^k   Jones, R ^l   Parker, C C ^d,m   Ritchie, A W S ^a   Russell, J M ^l   Millman, R ^a   Matheson, D ⁿ   Amos, C ^a   Gilson, C ^a   Birtle, A ^o   Brock, S ^p   Capaldi, L ^q   Chakraborti, P ^r   Choudhury, A ^s,t,u   Evans, L ^v   Ford, D ^w   Gale, J ^x   Gibbs, S ^y   Gilbert, D C ^z   Hughes, R ^aa   McLaren, D ^ab   Lester, J F ^ac   Nikapota, A ^ad   O'Sullivan, J ^ae,af   Parikh, O ^ag   Peedell, C ^ah   Protheroe, A ^ai   Rudman, S M ^f   Shaffer, R ^aj   Sheehan, D ^ak   Simms, M ^al   Srihari, N ^am   Strebel, R ^j,an   Sundar, S ^ao   Tolan, S ^k   Tsang, D ^ap   Varughese, M ^aq   Wagstaff, J ^ar   Parmar, M K B ^a   James, Nicholas D ^as   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c HOPE HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^g ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^h Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^k CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^l UNIVERSITY OF GLASGOW   (United Kingdom)

^m ROYAL MARSDEN HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^o ROYAL PRESTON HOSPITAL   (United Kingdom)

^p POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^q WORCESTERSHIRE ACUTE HOSPITALS NHS TRUST   (United Kingdom)

^r ROYAL DERBY HOSPITAL   (United Kingdom)

^s UNIVERSITY OF MANCHESTER   (United Kingdom)

^t UNIVERSITY OF MANCHESTER   (United Kingdom)

^u CHRISTIE HOSPITAL   (United Kingdom)

^v SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^w CITY HOSPITAL   (United Kingdom)

^x QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^y QUEEN S HOSPITAL   (United Kingdom)

^z ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^aa MOUNT VERNON HOSPITAL   (United Kingdom)

^ab WESTERN GENERAL HOSPITAL   (United Kingdom)

^ac VELINDRE CANCER CENTRE   (United Kingdom)

^ad Sussex Cancer Centre ^*  (United Kingdom)

^ae QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^af BELFAST CITY HOSPITAL   (United Kingdom)

^ag LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^ah SOUTH TEES HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^ai OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^aj ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^ak ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^al HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^am PRINCESS ROYAL HOSPITAL   (United Kingdom)

^an KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^ao NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^ap Sport and Public Services Department   (United Kingdom)

^aq MUSGROVE PARK HOSPITAL   (United Kingdom)

^ar SWANSEA UNIVERSITY   (United Kingdom)

^as UNIVERSITY OF BIRMINGHAM   (United Kingdom)

more..

Author keywords

Abiraterone; Docetaxel; Head to head; Prostate cancer; Randomised; Treatment

Indexed keywords

ABIRATERONE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; GONADORELIN DERIVATIVE; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; RADIUM; SIPULEUCEL T; ABIRATERONE ACETATE; ANTIANDROGEN; ANTINEOPLASTIC AGENT;

AGE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; DRUG SAFETY; DYSPNEA; EDEMA; ENDOCRINE DISEASE; FAILURE FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; GASTROINTESTINAL DISEASE; GLEASON SCORE; HAZARD RATIO; HEART ARRHYTHMIA; HEART INFARCTION; HORMONAL THERAPY; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOKALEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MUSCULOSKELETAL DISEASE; NEUTROPENIA; ORCHIECTOMY; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HEALTH CARE QUALITY; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; NETWORK META-ANALYSIS; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

ABIRATERONE ACETATE; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOCETAXEL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NETWORK META-ANALYSIS; PROGRESSION-FREE SURVIVAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STANDARD OF CARE;

EID: 85045001847     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy072     Document Type: Article

References (25)

1. Widmark A, Klepp O, Solberg A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373(9660): 301-308
2. Mason MD, Parulekar WR, Sydes MR et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. JCO 2015; 33(19): 2143-2150
3. Mottet N, Peneau M, Mazeron JJ et al. Addition of radiotherapy to longterm androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 2012; 62(2): 213-219
4. Fizazi K, Lesaunier F, Delva R et al. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Eur J Cancer 2012; 48(2): 209-217
5. Fizazi K, Faivre L, Lesaunier F et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 2015; 16(7): 787-794
6. Gravis G, Boher JM, Joly F et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial. Eur Urol 2016; 70(2): 256-262
7. James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387(10024): 1163-1177
8. Vale CL, Burdett S, Rydzewska LH et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and metaanalyses of aggregate data. Lancet Oncol 2016; 17(2): 243-256
9. Sweeney CJ, Chen YH, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373(8): 737-746
10. James ND, de Bono JS, Spears MR et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017; 377(4): 338-351
11. Fizazi K, Tran N, Fein L et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017; 377(4): 352-360
12. Sydes MR, Parmar MK, Mason MD et al. Flexible trial design in practice-stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials 2012; 13(1): 168
13. Parmar MK, Sydes MR, Cafferty FH et al. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: multi-arm, multi-stage platform, umbrella and basket protocols. Clinical Trials 2017; 14(5): 451-461
14. Sydes MR, Parmar MK, James ND et al. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials 2009; 10(1): 39
15. Xie W, Regan MM, BuyseMet al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. JCO 2017; 35(27): 3097-3104
16. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 2017; 377(1): 62-70
17. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368(2): 138-148
18. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival inmetastatic prostate cancer. N Engl J Med 2011; 364(21): 1995-2005
19. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376(9747): 1147-1154
20. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513-1520
21. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502-1512
22. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367(13): 1187-1197
23. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl JMed 2014; 371(5): 424-433
24. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369(3): 213-223
25. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363(5): 411-422